Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$5.82

0.22 (3.93%)

, UNH

UnitedHealth

$280.18

0.34 (0.12%)

08:09
12/09/19
12/09
08:09
12/09/19
08:09

UnitedHealth's OptumRx to acquire Diplomat Pharmacy for $4.00 per share in cash

OptumRx, the pharmacy care services business of Optum, part of UnitedHealth Group (UNH), and Diplomat Pharmacy (DPLO) announced earlier that they are combining. The agreement calls for the acquisition of Diplomat's outstanding common stock for $4.00 per share through a cash tender offer and assumption of outstanding debt. The transaction was unanimously approved by the board of directors of Diplomat. Diplomat co-founder and chairman emeritus Philip Hagerman and certain persons and entities affiliated with Mr. Hagerman own approximately 23% of the outstanding common stock of Diplomat, and have agreed to tender their shares in connection with the offer. "With its focus in specialty and infusion services, Diplomat has a proven track record of solving the unique challenges facing patients with complex health care needs," said John Prince, CEO of OptumRx. "This combination will expand the innovative specialty pharmacy and infusion solutions OptumRx can offer to the consumers and clients we serve, helping ensure people get the right medications and services at the right time, in the right setting."

DPLO

Diplomat Pharmacy

$5.82

0.22 (3.93%)

UNH

UnitedHealth

$280.18

0.34 (0.12%)

DPLO Diplomat Pharmacy
$5.82

0.22 (3.93%)

11/13/19
LEHM
11/13/19
DOWNGRADE
Target $3
LEHM
Equal Weight
Diplomat Pharmacy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Steven Valiquette downgraded Diplomat Pharmacy to Equal Weight from Overweight with a $3 price target.
11/13/19
LEHM
11/13/19
DOWNGRADE
Target $3
LEHM
Equal Weight
Barclays downgrades Diplomat Pharmacy, cuts target to $3 from $7
Barclays analyst Steven Valiquette downgraded Diplomat Pharmacy to Equal Weight from Overweight with a price target of $3, down from $7. Diplomat's strategic review is ongoing, which could lead to a sale of the entire company, or simultaneous asset sales that could unlock value, Valiquette tells investors in a research note. The analyst, however, says the company still face challenges when both competing against and negotiating with larger players in the pharmaceutical services sector. He reduced his projections for another customer loss in the core specialty pharmacy given Diplomat's inability to reach adequate reimbursement terms with a large payor.
11/13/19
11/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Hold from Buy at Canaccord with analyst T. Michael Walkley saying he believes the company is well positioned to grow faster than the broader semi market for the next several years due to smartphone mix among Chinese OEMs requiring integrated Rf solutions, growing IoT opportunities, and the ramping 5G market opportunities. 2. D.R. Horton (DHI) downgraded to Neutral from Buy at Buckingham. 3. Diplomat Pharmacy (DPLO) downgraded to Equal Weight from Overweight at Barclays with analyst Steven Valiquette saying Diplomat's strategic review is ongoing, which could lead to a sale of the entire company, or simultaneous asset sales that could unlock value. 4. Alcoa (AA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Timna Tanners citing limited catalysts and a cautious aluminum view, adding that while the stock price has risen about 16% since reporting Q3, aluminum price was up only about 6% in that time frame. 5. J.M. Smucker (SJM) downgraded to Underperform from Neutral at Credit Suisse with analyst Robert Moskow saying with consensus already below management's FY20 guidance of $8.35-$8.55, it is fair to say that J.M. Smucker is already an out-of-favor stock, but he believes that consensus and the market underestimate the extent to which earnings will need to be revised lower as structural challenges continue to mount. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/19
MSCO
11/15/19
NO CHANGE
Target $4
MSCO
Equal Weight
Diplomat Pharmacy 'bull case' value raised to $6 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser took a closer look at the potential take out value for Diplomat Pharmacy after the company said it is engaged in advanced discussions and has seen interest in both the whole company and its businesses, leading her to increase her "bull case scenario" value of the stock to $6 from $5. The specialty infusion business "has been the bright light in Diplomat's portfolio" and it could potentially be valued at $4 per share in a take out scenario, estimates Goldwasser. Recent industry conversations raise questions about what price a potential buyer would be willing to pay for the company's core specialty business, which could be worth $2 per share "depending on who the ultimate buyer is," Goldwasser added. She maintains an Equal Weight rating and $4 price target on Diplomat shares.
UNH UnitedHealth
$280.18

0.34 (0.12%)

12/04/19
CANT
12/04/19
NO CHANGE
Target $315
CANT
Overweight
UnitedHealth price target raised to $315 from $310 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for UnitedHealth Group to $315 from $310 saying the company's investor conference "went well." UnitedHealth's 2020 guidance was "solid, with some concern regarding the lackluster membership growth expectations for its commercial risk and fee-based businesses," Halper tells investors in a research note. After factoring in strong growth in Medicare and Medicaid, total UnitedHealthcare revenue was a bit below our expectations, says the analyst. However, Optum 2020 guidance was above Halper's estimates given strong growth in OptumHealth and OptumRx.
12/04/19
CANT
12/04/19
NO CHANGE
Target $315
CANT
Overweight
UnitedHealth price target raised to $315 from $310 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for UnitedHealth Group to $315 from $310 saying the company's investor conference "went well." UnitedHealth's 2020 guidance was "solid, with some concern regarding the lackluster membership growth expectations for its commercial risk and fee-based businesses," Halper tells investors in a research note. After factoring in strong growth in Medicare and Medicaid, total UnitedHealthcare revenue was a bit below our expectations, says the analyst. However, Optum 2020 guidance was above Halper's estimates given strong growth in OptumHealth and OptumRx.
12/04/19
BMOC
12/04/19
NO CHANGE
Target $310
BMOC
Market Perform
UnitedHealth price target raised to $310 from $285 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on UnitedHealth to $310 but kept his Market Perform rating after its Investor Day. The analyst notes that the company's presentation offered a "credible, clear, and detailed road map for 2020" driven by strength in Optum, Medicare, and Medicaid while being offset by a "somewhat sluggish" commercial outlook and a "temporary headwind" from the health insurer fee. Borsch adds that UnitedHealth looks to be "past the point" of significant downside risk, and its "strong" earnings growth demonstrates its cost-competitive advantage over its peers.
12/05/19
RAJA
12/05/19
NO CHANGE
Target $320
RAJA
Strong Buy
UnitedHealth price target raised to $320 from $300 at Raymond James
Raymond James analyst John Ransom raised his price target for UnitedHealth to $320 from $300 following the company's investor day where management shared their comprehensive initial 2020 outlook while also updating 2019 guidance. In a research note to investors, Ransom says he continues to see UnitedHealth's ability to utilize its diverse mix of services to lower risk and drive long-term value for shareholders with management targeting 8%-11% organic annual EPS growth with an additional 3%-5% benefit from capital allocation. The analyst also notes that management's guidance has historically proven conservative as they take a middle-of-the-road approach to including the impact of cost-saving initiatives.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$13.51

-0.135 (-0.99%)

, PUGOY

Peugeot

$0.00

(0.00%)

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Periodicals
Fiat Chrysler CEO says PSA deal talks 'progressing really well,' Reuters says »

Fiat Chrysler (FCAU) CEO…

FCAU

Fiat Chrysler

$13.51

-0.135 (-0.99%)

PUGOY

Peugeot

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.66

0.345 (6.49%)

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
01/22/20
01/22
12:25
01/22/20
12:25
Conference/Events
The Executives' Club of Chicago to hold a luncheon meeting »

The Executives' Club…

SRPT

Sarepta

$121.03

-1.65 (-1.34%)

12:24
01/22/20
01/22
12:24
01/22/20
12:24
Periodicals
New documents point to 'deeper' FDA concerns about Sarepta's Vyondys, STAT says »

New documents released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTI

Proteostasis

$1.96

0.04 (2.08%)

12:17
01/22/20
01/22
12:17
01/22/20
12:17
Hot Stocks
Proteostasis to present data from organoid study in CF treatment »

Proteostasis Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
01/22/20
01/22
12:17
01/22/20
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNA

Moderna

$21.97

1 (4.77%)

12:16
01/22/20
01/22
12:16
01/22/20
12:16
Recommendations
Moderna analyst commentary  »

Moderna mRNA technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
01/22/20
01/22
12:16
01/22/20
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
01/22/20
01/22
12:15
01/22/20
12:15
General news
Oil Action: WTI crude »

Oil Action: WTI crude hit…

TWLO

Twilio

$119.62

0.47 (0.39%)

12:12
01/22/20
01/22
12:12
01/22/20
12:12
Periodicals
Breaking Periodicals news story on Twilio »

Hedgeye adds Twilio to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 24

    Feb

NFLX

Netflix

$332.00

-6.24 (-1.84%)

, IBM

IBM

$143.22

4.07 (2.92%)

12:12
01/22/20
01/22
12:12
01/22/20
12:12
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are rebounding…

NFLX

Netflix

$332.00

-6.24 (-1.84%)

IBM

IBM

$143.22

4.07 (2.92%)

AAPL

Apple

$318.43

2.04 (0.64%)

ETN

Eaton

$97.23

2.72 (2.88%)

ABT

Abbott

$92.33

2.57 (2.86%)

NAVI

Navient

$15.02

1.16 (8.37%)

ARNC

Arconic

$28.60

-0.795 (-2.71%)

FCEL

FuelCell

$2.14

-0.735 (-25.61%)

NTRS

Northern Trust

$102.32

-6.35 (-5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 27

    Jan

  • 28

    Jan

  • 04

    Feb

NTDOY

Nintendo

$0.00

(0.00%)

12:09
01/22/20
01/22
12:09
01/22/20
12:09
Periodicals
Judge says iLife's patent suit against Nintendo not valid, Verge says »

Federal Judge Barbara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WILC

G. Willi-Food

$12.22

-0.21 (-1.69%)

12:06
01/22/20
01/22
12:06
01/22/20
12:06
Hot Stocks
G. Willi-Food CEO Michael Luboschitz to resign for personal reasons »

G. Willi-Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.41

0.77 (2.51%)

12:05
01/22/20
01/22
12:05
01/22/20
12:05
Options
Elanco Animal Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 23

    Jan

HUYA

Huya

$18.73

-1.75 (-8.54%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Huya falls -8.5% »

Huya is down -8.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMRE

Costamare

$9.01

-1.34 (-12.95%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Costamare falls -12.9% »

Costamare is down -12.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CANG

Cango

$7.28

-0.71 (-8.89%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Cango falls -9.3% »

Cango is down -9.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCFT

OneConnect

$15.17

1.2 (8.59%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
OneConnect rises 8.5% »

OneConnect is up 8.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Periodicals
Bombardier subway cars returning to service this week in NYC, Reuters says »

Bombardier subway cars…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

FSB

Franklin Financial Network

$38.25

4.13 (12.10%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Franklin Financial Network rises 12.6% »

Franklin Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$4.88

0.73 (17.59%)

12:00
01/22/20
01/22
12:00
01/22/20
12:00
Hot Stocks
Express rises 17.5% »

Express is up 17.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

BTI

British American Tobacco

$44.63

0.06 (0.13%)

11:56
01/22/20
01/22
11:56
01/22/20
11:56
Upgrade
British American Tobacco rating change  »

British American Tobacco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$64.32

-0.24 (-0.37%)

11:55
01/22/20
01/22
11:55
01/22/20
11:55
Options
Spirit AeroSystems put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HARL

Harleysville Savings Financial Corp

$0.00

(0.00%)

11:53
01/22/20
01/22
11:53
01/22/20
11:53
Earnings
Harleysville reports Q1 EPS 50c vs. 57c last year »

Q1 net income included a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

HARL

Harleysville Savings Financial Corp

$0.00

(0.00%)

11:51
01/22/20
01/22
11:51
01/22/20
11:51
Hot Stocks
Harleysville increases quarterly cash dividend 8% »

Harleysville Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.